INTEGRATED CORE STRATEGIES (US) LLC 13D and 13G filings for Corvus Pharmaceuticals, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2023-01-30 4:17 pm Sale |
2022-12-31 | 13G | Corvus Pharmaceuticals, Inc. CRVS |
INTEGRATED CORE STRATEGIES (US) LLC | 1,899,516 4.100% |
-1,020,543 (-34.95%) |
Filing |
| 2022-01-18 4:55 pm Purchase |
2021-12-31 | 13G | Corvus Pharmaceuticals, Inc. CRVS |
INTEGRATED CORE STRATEGIES (US) LLC | 2,920,059 6.300% |
403,531 (+16.04%) |
Filing |
| 2021-12-06 4:44 pm Purchase |
2021-12-01 | 13G | Corvus Pharmaceuticals, Inc. CRVS |
INTEGRATED CORE STRATEGIES (US) LLC | 2,516,528 5.400% |
487,927 (+24.05%) |
Filing |
| 2021-10-22 4:36 pm Purchase |
2021-10-12 | 13G | Corvus Pharmaceuticals, Inc. CRVS |
INTEGRATED CORE STRATEGIES (US) LLC | 2,028,601 4.800% |
2,028,601 (New Position) |
Filing |